NASDAQ:CLDX Celldex Therapeutics Q2 2024 Earnings Report $32.45 -0.06 (-0.18%) Closing price 04:00 PM EasternExtended Trading$33.25 +0.80 (+2.47%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Celldex Therapeutics EPS ResultsActual EPS-$0.54Consensus EPS -$0.59Beat/MissBeat by +$0.05One Year Ago EPSN/ACelldex Therapeutics Revenue ResultsActual Revenue$2.50 millionExpected Revenue$1.13 millionBeat/MissBeat by +$1.37 millionYoY Revenue GrowthN/ACelldex Therapeutics Announcement DetailsQuarterQ2 2024Date8/8/2024TimeAfter Market ClosesConference Call DateThursday, August 8, 2024Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Celldex Therapeutics Earnings HeadlinesAssessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed SignalsMay 13 at 12:59 PM | finance.yahoo.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of "Moderate Buy" by AnalystsMay 12 at 2:13 AM | americanbankingnews.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 14 at 1:00 AM | Brownstone Research (Ad)Celldex Therapeutics (NASDAQ:CLDX) Stock Price Expected to Rise, Barclays Analyst SaysMay 10, 2026 | americanbankingnews.comCelldex Therapeutics, Inc.: Celldex Reports First Quarter Financial Results and Provides Corporate UpdateMay 8, 2026 | finanznachrichten.deCelldex Reports First Quarter Financial Results and Provides Corporate UpdateMay 7, 2026 | globenewswire.comSee More Celldex Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email. Email Address About Celldex TherapeuticsCelldex Therapeutics (NASDAQ:CLDX) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity. Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers. Other investigational compounds include varlilumab, an agonist antibody targeting CD27, CDX-301, a recombinant human Flt3 ligand designed to expand dendritic and immune cell populations, and CDX-1140, an antibody targeting CD40 to activate antigen-presenting cells. These programs are in various stages of clinical development, and Celldex collaborates with academic centers and industry partners to advance trials in the United States and select international sites. Founded in 1997 and headquartered in Hampton, New Jersey, Celldex has evolved from a small discovery lab into a specialized immunotherapy company. Under the leadership of President and Chief Executive Officer Roger F. Dansey, M.D., the organization has strengthened its scientific expertise and manufacturing capabilities to support both early-stage and later-stage development activities. Celldex serves patients primarily in North America while maintaining strategic relationships to facilitate broader access to its investigational therapies in other regions.View Celldex Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles YETI Rallies After Earnings Beat and Raised OutlookCisco’s Vertical Rally May Still Be in the Early InningsHow the 3 Leading Quantum Firms Stack Up After Q1 EarningsNebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunAmazon vs. Alibaba: One Is Clearly The Better Value Play right NowD-Wave Earnings Looked Weak, But Investors May Be Missing This Upcoming Earnings Mizuho Financial Group (5/15/2026)Baidu (5/18/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
